CD40 and graft versus host disease: Human leukocyte antigens (e.g., HLA-ABC and HLA-DR) and co-stimulatory molecules (e.g., CD40 and CD252) play a central role in adaptive immunity and therefore are the dominant polymorphic proteins targeted in GVHD and allograft rejection [32].